Antiviral activity of Bifidobacterium adolescentis SPM1605 against coxsackievirus B3

Biotechnology and Biotechnological Equipment

Volumn 28, Issue 4, 2014, Pages 681-688

  Kim, Min Ji ^a   Lee, Do Kyung ^a   Park, Jae Eun ^a   Park, Il Ho ^a   Seo, Jae Gu ^b   Ha, Nam Joo ^a  

^a Sahmyook University   (South Korea)

^b Bio Medical Science   (South Korea)

Author keywords

Bifidobacterium adolescentis; Coxsackievirus; HeLa cells; plaque reduction assay; real time qPCR

Indexed keywords

BACTERIA; DISEASE CONTROL; GENE EXPRESSION; POLYMERASE CHAIN REACTION; PROBIOTICS;

ALTERNATIVE THERAPY; ANTIVIRAL ACTIVITIES; BIFIDOBACTERIUM ADOLESCENTIS; BIFIDOBACTERIUM LONGUM; CELLULAR TOXICITIES; COXSACKIEVIRUS; HELA CELL; REAL TIME QPCR;

LANTHANUM COMPOUNDS;

BIFIDOBACTERIUM ADOLESCENTIS; COXSACKIEVIRUS;

EID: 84910088840     PISSN: 13102818     EISSN: None     Source Type: Journal    
DOI: 10.1080/13102818.2014.945237     Document Type: Article

References (32)

1. Luana Y, Daib HL, Yangb D, Zhub L, Gaob TL, Shaob HJ, Pengb X, Jin ZF. Small interfering RNA against the 2C genomic region of Coxsackievirus B3 exerts potential antiviral effects in permissive HeLa cells. Virus Res J. 2012;163:183-189.
2. Riabi S, Gaaloul I, Harrath R, Aouni M. Persistent infection of human intestinal Caco-2 cell line by Coxsackieviruses B. Pathol Biol. 2012;60:347-351.
3. Wang T, Yu B, Lin L, Zhai X, Han Y, Qin Y, Guo Z, Wu S, Zhong X, Wang Y, Tong L, Zhang F, Si X, Zhao W, Zhong Z. A functional nuclear localization sequence in the VP1 capsid protein of Coxsackievirus B3. Virology. 2012;433:513-521.
4. Zhang Y, Cao W, Xie YH, Yang Q, Li XQ, Liu XX, Wang SW. The comparison of a-bromo-4-chlorocinnamaldehyde and cinnamaldehyde on Coxsackie virus B3-induced myocarditis and their mechanisms. Int Immunopharmacol. 2012;14:107-113.
5. Chung SY, Cho YJ, Kim YJ, Kim DS, Lee H, Nam JH. Development of peptide antibody against Coxsackievirus B3 VP2. J Bacteriol Virol. 2006;36:109-117.
6. Rassmann A, Henke A, Jarasch N, Lottspeich F, Saluz HP, Munder T. The human fatty acid synthase: a new therapeutic target for Coxsackievirus B3-induced diseases? Antivir Res. 2007;76:150-158.
7. Shim SH, Kim YJ, Kim DS, Nam JH. Development of a gene therapy method for cervical cancer using attenuated Coxsackievirus B3 as a vector system. J Bacteriol Virol. 2011;41:123-130.
8. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano G. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis. 2007;44:79-86.
9. Schmidtke M, Schnittler U, Jahn B, Dahse H, Stelzner A. A rapid assay for evaluation of antiviral activity against Coxsackievirus B3, Influenza virus A, and Herpes simplex virus type 1. J Virol Methods. 2001;95:133-143.
10. Kishimoto C, Crumpacker CS, Abelmann WH. Ribavirin treatment of Coxsackie B3 myocarditis with analysis of lymphocyte subsets. J Am Coll Cardiol. 1988;12:1334-1341.
11. Rezkalla Shereif H, Raikar Sharmishtha K, Robert A. Treatment of viral myocarditis with focus on captopril. Am J Cardiol. 1996;77:634-637.
12. Petros AM, Walter C, Lidija G, Effie T, Avrelija C. Lactic acid bacteria efficiently protect human and animal intestinal ephithelial and immune cells from enteric virus infection. Int J Food Microbiol. 2010;141:591-597.
13. Colb-ere-Garapin F, Martin-Latil S, Blondel B, Mousson L, Pelletier I, Autret A, Francois A, Niborski V, Grompone G, Catonnet G, van de Moer A. Prevention and treatment of enteric viral infections: possible benefits of probiotic bacteria. Microbes Infect. 2007;9:1623-1631.
14. Boti-ca T, Klingbergb TD, Weingartlc H, Cenci-c A. A novel eukaryotic cell culture model to study antiviral activity of potential probiotic bacteria. Int J Food Microbiol. 2007;115:227-234.
15. Ivec M, Boti-c T, Koren S, Jakobsen M, Weingartl H, Cencic A. Interactions of macrophages with probiotic bacteria lead to increased antiviral response against vesicular stomatitis virus. Antivir Res. 2007;75:266-274.
16. De Vrese M, Winkler P, Rautenberg P, Harder T, Noah C, Laue C, Ott S, Hampe J, Schreiber S, Heller K, Schrezenmeir J. Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial. Vaccine. 2006;24:6670-6674.
17. Youn HN, Lee DH, Lee YN, Park JK, Yuk SS, Yang SY, Lee H., Woo SH, Kim HM, Lee JB, Park SY, Choi IS, Song CS. Intranasal administration of live Lactobacillus species facilitates protection against Influenza virus infection in mice. Antivir Res. 2012;93:138-143.
18. An HM, Lee DK, Kim JR, Lee SW, Cha MK, Lee KO, Ha NJ. Antiviral activity of Bifidobacterium adolescentis SPM 0214 against Herpes simplex virus type 1. Arch Pharm Res. 2012;35:1665-1671.
19. Yua Z, Huanga Z, Saob C, Huangb Y, Zhanga F, Yanga J, Liana J, Zenga Z, Luoc W, Zenga W, Denga Q. Bifidobacterium as an oral delivery carrier of Interleukin-12 for the treatment of Coxsackievirus B3-induced myocarditis in the Balb/c mice. Int Immunopharmacol. 2012;12:125-130.
20. Watkins RT, Woegerbauer M, Hollemann D, Hufnagl P. Rapid diagnosis of Enterovirus infections by real-time PCR on the LightCycler using the TaqMan format. Diagn Microbiol Infect Dis. 2002;42:99-105.
21. Krieg NR, Holt JG. In Bergey’s manual of systematic bacteriology. Vol. 1. The Williams & Wilkins Co.; 1984. p. 1418-1434.
22. Ahn JB. Isolation and characterization of Bifidobacterium producing exopolysaccharide. Food Eng Prog. 2005;9:291-296.
23. Ahn JH, Jun ES, Lee H., Yoon SY, Kim D, Joo CH, Kim YK, Lee H. A small interfering RNA targeting Coxsackievirus B3 protects permissive HeLa cells from viral challenge. J Virol. 2005;79:8620-8624.
24. Verstrepen WA, Kuhn S, Kockx MM, Van De Vyvere ME, Mertens AH. Rapid detection of Enterovirus RNA in cerebrospinal fluid specimens with a novel single-tube realtime reverse transcription-PCR assay. J Clin Microbiol. 2001;39:4093-4096.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 22DDCT method. Methods. 2001;25:402-408.
26. Cha MK, Lee DK, An HM, Lee SW, Shin SH, Kwon JH, Kim KJ, Ha NJ. Antiviral activity of Bifidobacterium adolescentis SPM1005-A on Human papillomavirus typeo 16. BMC Med. 2012;10:72. doi:10.1186/1741-7015-10-72
27. Picard C, Fioramonti J, Francois A, Robinson T, Neant F, Matuchansky C. Bifidobacteria as probiotic agents-physiological effects and clinical benefits. Aliment Pharmacol Ther. 2005;22:495-512.
28. Guandalini S, Pensabene L, Zikri MA, Dias JA, Casali LG, Hoekstra H, Kolacek S, Massar K, Micetic-Turk D, Papadopoulou A, de Sousa JS, Sandhu B, Szajewska H, Weizman Z. Laclobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. 2000;30:54-60.
29. Rosenfeldt V, Michaelsen KF, Jakobsen M, Larsen CN, Moller PL, Pedersen P, Tvede M, Weyrehter H, Valerius NH, Paerregaard A. Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea. Pediatr Infect Dis. 2002;21:411-416.
30. Lee DK, Kang JY, Shin HS, Park IH, Ha NJ. Antiviral activity of Bifidobacterium adolescentis SPM0212 against Hepatitis B virus. Arch Pharm Res. 2013;36 (12):1525-1532. doi:10.1007/s12272-013-0141-3
31. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008;8:559-568.
32. Chieux V, Chehadeh W, Harvey J, Haller O, Wattr-e P, Hober D. Inhibition of Coxsackievirus B4 replication in stably transfected cells expressing human MxA protein. Virology. 2001;283:84-92.